1. Home
  2. DHY vs ZVRA Comparison

DHY vs ZVRA Comparison

Compare DHY & ZVRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

DHY

Credit Suisse High Yield Bond Fund

BUY

Current Price

$16.23

Market Cap

240.4M

Sector

Finance

ML Signal

BUY

Logo Zevra Therapeutics Inc.

ZVRA

Zevra Therapeutics Inc.

SELL

Current Price

$10.32

Market Cap

689.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
DHY
ZVRA
Founded
N/A
2006
Country
United States
United States
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
240.4M
689.4M
IPO Year
1998
2015

Fundamental Metrics

Financial Performance
Metric
DHY
ZVRA
Price
$16.23
$10.32
Analyst Decision
Strong Buy
Analyst Count
0
9
Target Price
N/A
★ $25.00
AVG Volume (30 Days)
724.8K
★ 849.5K
Earning Date
01-01-0001
11-04-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 159.21
EPS
N/A
★ 0.74
Revenue
N/A
★ $106,470,000.00
Revenue This Year
N/A
$43.97
Revenue Next Year
N/A
$15.93
P/E Ratio
★ N/A
$15.30
Revenue Growth
N/A
★ 350.91
52 Week Low
$1.61
$8.01
52 Week High
$16.67
$15.04

Technical Indicators

Market Signals
Indicator
DHY
ZVRA
Relative Strength Index (RSI) 97.12 39.50
Support Level $1.77 $10.07
Resistance Level $16.67 $11.07
Average True Range (ATR) 0.23 0.48
MACD 0.72 0.01
Stochastic Oscillator 97.01 34.14

Price Performance

Historical Comparison
DHY
ZVRA

About DHY Credit Suisse High Yield Bond Fund

Credit Suisse High Yield Credit Fund is a diversified, closed-end management investment company. The Fund's principal investment objective is to generate current income. Capital appreciation is a secondary objective, pursued to the extent consistent with the Fund's primary income objective.

About ZVRA Zevra Therapeutics Inc.

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

Share on Social Networks: